Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Hematology

The Long Game: Monitoring, Relapse, and Quality of Life

At a Glance

Long-term care for Waldenström macroglobulinemia uses regular check-ups and blood tests, often every 3 to 6 months, to track disease activity and treatment effects. If the disease relapses, options depend on previous treatment, response, and tolerance.

Because Waldenström macroglobulinemia (WM) is an indolent, chronic disease, your relationship with your medical team will likely span many years. For many, the journey involves long periods of stability followed by occasional adjustments in treatment. Managing this “long game” requires a shift in focus from curing the disease to maintaining your quality of life and staying vigilant without letting the diagnosis take over your identity [1][2].

The Surveillance Schedule: Your Routine “Check-Ups”

Whether you are currently in “watch and wait” or have completed a round of treatment, regular monitoring is the standard of care. This allows your team to catch subtle changes before they become serious [3].

  • Frequency: For most stable patients, check-ups occur every 3 to 6 months [3][4].
  • Physical Exam: Your doctor will check for enlarged lymph nodes, a swollen spleen or liver, and any new signs of nerve damage [3].
  • Core Blood Tests:
    • CBC (Complete Blood Count): To monitor for anemia (low red cells) or low platelets [5].
    • Quantitative IgM: To track the “burden” of the disease [6].
    • SPEP/IFE: These detailed protein tests help confirm that the IgM being measured is actually the “M-protein” from the lymphoma [6].
    • CMP (Comprehensive Metabolic Panel): To check your kidney and liver health [5].
  • Imaging and Biopsy: Unlike other cancers, you may not need routine CT or PET scans. Scans and repeat bone marrow biopsies are usually reserved for times when your lab work changes significantly or you develop new symptoms [7][8].

Navigating “Scanxiety” and Uncertainty

Living with a slow-growing, incurable cancer can create a unique psychological burden. You may experience scanxiety—a spike in stress in the days or weeks leading up to a follow-up appointment [9].

The “watch and wait” period is often the most difficult mentally. It can feel counterintuitive to leave a cancer untreated. Remind yourself that “watching” is an active clinical strategy designed to save more aggressive treatments for when you truly need them, thereby avoiding unnecessary side effects [5]. If the uncertainty feels overwhelming, some patients find that working with a psycho-oncologist or joining a WM-specific support group helps normalize these feelings [10].

What Happens if the Cancer Returns?

If your disease progresses—often called a relapse—it does not mean you have run out of options. The “next step” depends on what treatment you had before and how long it lasted [11].

  1. Retreatment: If you had a great response to chemoimmunotherapy (like BR) that lasted for more than 3 years, your doctor might suggest using that same regimen again [12][13].
  2. Switching BTK Inhibitors (for intolerance): If you were taking ibrutinib but had to stop because of side effects (intolerance, like heart palpitations), you might switch to a different “covalent” BTK inhibitor like zanubrutinib, which is often better tolerated [14]. (Note: If you progress on a BTKi, switching to another drug in the same class is generally not recommended).
  3. Newer Targeted Therapies: If the cancer has become resistant to standard BTK inhibitors, newer “non-covalent” inhibitors like pirtobrutinib or the BCL-2 inhibitor venetoclax have shown high response rates in trials [15][16]. (Approval status for these varies, and they may be available primarily as off-label prescriptions or through clinical trials).

(Crucial Warning: Never abruptly stop or restart a BTK inhibitor on your own, especially after progression, as a dangerous IgM rebound or rapid symptom worsening can occur).

Daily Management and Quality of Life

Your long-term health depends on managing the “side effects” of both the disease and its treatments:

  • Peripheral Neuropathy: This remains a top concern for many. While some treatments can improve neuropathy, the goal is often to prevent it from getting worse [17]. Tracking your ability to perform tasks like buttoning a shirt or walking can help your doctor adjust your care [18].
  • Infection Risk: Both WM and its treatments can weaken your immune system [19]. Staying up-to-date on vaccines is critical, but timing must be coordinated with your doctor and live vaccines should generally be avoided while severely immunosuppressed. If you have a history of Hepatitis B, or even if you do not, you need special mandatory screening before anti-CD20 therapy (like rituximab) to prevent the virus from reactivating [20].
  • Bleeding Risk: Because IgM can interfere with clotting and some treatments like BTK inhibitors can cause easier bruising, you should always inform your medical team (and your dentist) before any surgery or procedure [21][22]. Review all anticoagulants and NSAIDs with your doctor.

Common questions in this guide

How often should I have follow-up visits for Waldenström macroglobulinemia?
For many people with stable WM, follow-up visits occur every 3 to 6 months, although your schedule may change based on treatment and symptoms. Visits commonly include a physical examination and blood tests such as a complete blood count, quantitative IgM, protein testing, and a metabolic panel.
Which tests are used to monitor WM over time?
Monitoring usually includes blood counts, quantitative IgM, serum protein electrophoresis and immunofixation (SPEP/IFE), and a comprehensive metabolic panel to assess disease activity and organ health. CT or PET scans and repeat bone marrow biopsies are generally reserved for substantial laboratory changes or new symptoms rather than performed at every routine visit.
Does watch and wait mean my Waldenström cancer is being ignored?
No. Watch and wait is active monitoring for people who do not currently need treatment, with planned visits and tests to detect meaningful changes. It can delay treatment-related side effects while preserving options for when treatment becomes necessary.
What treatment options are available if WM comes back?
Treatment after relapse depends on the treatment you received before, how well it worked, how long the response lasted, and why it was stopped. If a chemoimmunotherapy response lasted more than three years, the same regimen may sometimes be considered again; newer targeted medicines or a clinical trial may be options in other situations. Your hematology-oncology team should determine which option is appropriate.
Can I change or stop a BTK inhibitor if I have side effects?
A person who stops ibrutinib because of side effects may sometimes switch to another covalent BTK inhibitor, such as zanubrutinib, under medical supervision. If the disease progressed on a BTK inhibitor, switching within the same class is generally not recommended, and no BTK inhibitor should be stopped or restarted without medical guidance because IgM can rebound.
How can I protect my quality of life and reduce infection or bleeding risks?
Tell your team about numbness, difficulty with tasks or walking, fatigue, bruising, or bleeding so care can be adjusted. Coordinate vaccines with your clinician, avoid live vaccines when severely immunosuppressed, complete hepatitis B screening before anti-CD20 treatment, and review anticoagulants and NSAIDs before procedures.
How can I manage anxiety during WM watch and wait?
Stress before follow-up visits, sometimes called scanxiety, is common when living with a chronic cancer. A psycho-oncologist, a WM-specific support group, and an honest conversation with your care team may help you manage uncertainty without interpreting every new ache as relapse.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Waldenström macroglobulinemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How often will we be checking my IgM levels and blood counts while I am in 'watch and wait' or post-treatment?
  2. 2.What specific lab changes or physical symptoms would signal that my cancer is relapsing?
  3. 3.If my cancer returns, would I be a candidate for a newer targeted therapy, or a clinical trial?
  4. 4.How can we better manage my fatigue or neuropathy to improve my daily quality of life?
  5. 5.Since imaging like PET scans can sometimes be inconsistent in WM, how much weight are we giving to my 'M-protein' levels versus my scan results?
  6. 6.Do I need any specific vaccines, and what is the safe timing for them regarding my treatments?

References

References (22)
  1. 1

    Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas.

    Leslie LA

    Current treatment options in oncology 2021; (22(12)):111 doi:10.1007/s11864-021-00909-1.

    PMID: 34694508
  2. 2

    Waldenstrom macroglobulinemia: prognosis and management.

    Oza A, Rajkumar SV

    Blood cancer journal 2015; (5()):e394 doi:10.1038/bcj.2015.28.

    PMID: 25815903
  3. 3

    SOHO State of the Art Updates and Next Questions: Waldenström Macroglobulinemia - 2021 Update on Management and Future Directions.

    Thomas SK

    Clinical lymphoma, myeloma & leukemia 2022; (22(6)):347-355 doi:10.1016/j.clml.2021.11.014.

    PMID: 34980578
  4. 4

    Initial Evaluation of the Patient with Waldenström Macroglobulinemia.

    Castillo JJ, Treon SP

    Hematology/oncology clinics of North America 2018; (32(5)):811-820 doi:10.1016/j.hoc.2018.05.008.

    PMID: 30190019
  5. 5

    Waldenström Macroglobulinemia: 2025 Update on Diagnosis, Risk Stratification, and Management.

    Gertz MA

    American journal of hematology 2025; (100(6)):1061-1073 doi:10.1002/ajh.27666.

    PMID: 40095219
  6. 6

    Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria.

    Treon SP, Tedeschi A, San-Miguel J, et al.

    Seminars in hematology 2023; (60(2)):97-106 doi:10.1053/j.seminhematol.2023.03.009.

    PMID: 37173155
  7. 7

    68 Ga-pentixafor PET/CT Indicates Inconsistent Response With Monoclonal Protein-based Response Criteria in Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Patients Treated With Bruton Tyrosine Kinase Inhibitors.

    Pan Q, Liu S, Zhang H, et al.

    Clinical nuclear medicine 2026; (51(8)):637-643 doi:10.1097/RLU.0000000000006518.

    PMID: 42113823
  8. 8

    Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.

    Kumar SK, Callander NS, Adekola K, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2024; (22(1D)):e240001.

    PMID: 38244272
  9. 9

    Current and new approaches to the treatment landscape for adults with Waldenström macroglobulinemia.

    Edwards CV, Castillo JJ, Mouhieddine TH, Sarosiek SR

    Expert opinion on pharmacotherapy 2026; 1-14 doi:10.1080/14656566.2026.2734125.

    PMID: 42745460
  10. 10

    Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trial.

    Tedeschi A, Tam CS, Owen RG, et al.

    Future oncology (London, England) 2024; (20(25)):1789-1798 doi:10.1080/14796694.2024.2355079.

    PMID: 39072392
  11. 11

    Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients.

    D'Sa S, Matous JV, Advani R, et al.

    Seminars in hematology 2023; (60(2)):80-89 doi:10.1053/j.seminhematol.2023.03.003.

    PMID: 37147252
  12. 12

    Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.

    Kapoor P, Ansell SM, Fonseca R, et al.

    JAMA oncology 2017; (3(9)):1257-1265 doi:10.1001/jamaoncol.2016.5763.

    PMID: 28056114
  13. 13

    Long-term follow-up of venetoclax monotherapy in previously treated patients with Waldenström macroglobulinemia.

    Castillo JJ, Guijosa A, Allan JN, et al.

    Blood advances 2025; (9(19)):4842-4847 doi:10.1182/bloodadvances.2025016890.

    PMID: 40674749
  14. 14

    Optimizing BTK Inhibition in Waldenström Macroglobulinemia.

    Sarosiek S, Castillo JJ

    Journal of the National Comprehensive Cancer Network : JNCCN 2024; (22(4)).

    PMID: 38754469
  15. 15

    Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial.

    Palomba ML, Patel MR, Eyre TA, et al.

    The Lancet. Haematology 2026; (13(5)):e284-e296 doi:10.1016/S2352-3026(26)00037-2.

    PMID: 42069409
  16. 16

    Venetoclax in Previously Treated Waldenström Macroglobulinemia.

    Castillo JJ, Allan JN, Siddiqi T, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022; (40(1)):63-71 doi:10.1200/JCO.21.01194.

    PMID: 34793256
  17. 17

    Prevalence and Disability of Peripheral Neuropathy in Patients With Waldenström's Macroglobulinemia.

    Aagaard MM, Skaastrup KN, Kodal LS, et al.

    European journal of haematology 2026; doi:10.1111/ejh.70316.

    PMID: 42695760
  18. 18

    Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia.

    Heyman BM, Opat SS, Wahlin BE, et al.

    Blood advances 2025; (9(4)):722-728 doi:10.1182/bloodadvances.2024014115.

    PMID: 39626287
  19. 19

    Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study.

    Owen RG, McCarthy H, Rule S, et al.

    The Lancet. Haematology 2020; (7(2)):e112-e121 doi:10.1016/S2352-3026(19)30210-8.

    PMID: 31866281
  20. 20

    Impact of Comorbidities on Patients With Waldenström Macroglobulinemia in Taiwan: A Multicenter Study.

    Chang YS, Tuan YH, Gao JW, et al.

    JCO global oncology 2025; (11()):e2400576 doi:10.1200/GO-24-00576.

    PMID: 40215436
  21. 21

    Bleeding Propensity in Waldenström Macroglobulinemia: Potential Causes and Evaluation.

    Brysland SA, Maqbool MG, Talaulikar D, Gardiner EE

    Thrombosis and haemostasis 2022; (122(11)):1843-1857 doi:10.1055/a-1896-7092.

    PMID: 35817084
  22. 22

    Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up.

    Trotman J, Opat S, Gottlieb D, et al.

    Blood 2020; (136(18)):2027-2037 doi:10.1182/blood.2020006449.

    PMID: 32698195

This page is for informational purposes only and does not constitute medical advice about Waldenström macroglobulinemia. Your hematology and oncology team should personalize monitoring, vaccination, and treatment decisions for your situation.